{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:52:41Z","timestamp":1787730761358,"version":"build-2784847793"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13300-025-01774-z","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:05:15Z","timestamp":1753869915000},"page":"1763-1777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fenofibrate and Diabetic Retinopathy"],"prefix":"10.1007","volume":"16","author":[{"given":"A.","family":"Parra-Pineda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lizarazo-Bocanegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Villalba-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Ayala-Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Losada-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Correa-Osio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Lizarazo-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-4206","authenticated-orcid":false,"given":"C. O.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1774_CR1","unstructured":"International Diabetes Federation. IDF Atlas, 11th Edition, 2025. www.diabetesatlas.org."},{"key":"1774_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","volume":"44","author":"IM Stratton","year":"2001","unstructured":"Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156\u201363.","journal-title":"Diabetologia"},{"key":"1774_CR3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot Care: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(S1):S252-S265.","DOI":"10.2337\/dc25-S012"},{"key":"1774_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107840","volume":"157","author":"RL Thomas","year":"2019","unstructured":"Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157: 107840.","journal-title":"Diabetes Res Clin Pract"},{"key":"1774_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41433-024-03101-5","volume":"38","author":"Vision Loss Expert Group of the Global Burden of Disease Study","year":"2024","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020. Eye (Lond). 2024;38:2047\u201357.","journal-title":"Eye (Lond)"},{"key":"1774_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng CY. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"1774_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0014-5793(97)01159-9","volume":"416","author":"SS Korshunov","year":"1997","unstructured":"Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997;416:15\u20138.","journal-title":"FEBS Lett"},{"key":"1774_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1172\/JCI18127","volume":"112","author":"X Du","year":"2003","unstructured":"Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112:1049\u201357.","journal-title":"J Clin Invest"},{"key":"1774_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615\u201325.","journal-title":"Diabetes"},{"key":"1774_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1074\/jbc.C600268200","volume":"282","author":"DR Dries","year":"2007","unstructured":"Dries DR, Gallegos LL, Newton AC. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J Biol Chem. 2007;282:826\u201330.","journal-title":"J Biol Chem"},{"key":"1774_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1172\/JCI119503","volume":"100","author":"D Koya","year":"1997","unstructured":"Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100:115\u201326.","journal-title":"J Clin Invest"},{"key":"1774_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/01.CIR.101.6.676","volume":"101","author":"K Kuboki","year":"2000","unstructured":"Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676\u201381.","journal-title":"Circulation"},{"key":"1774_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1097-2765(03)00246-6","volume":"12","author":"MI Wilson","year":"2003","unstructured":"Wilson MI, Gill DJ, Perisic O, Quinn MT, Williams RL. PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. Mol Cell. 2003;12:39\u201350.","journal-title":"Mol Cell"},{"key":"1774_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4093\/dmj.2018.0182","volume":"42","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A. Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J. 2018;42:364\u201376.","journal-title":"Diabetes Metab J"},{"key":"1774_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jare.2024.01.016","volume":"67","author":"G Li","year":"2025","unstructured":"Li G, Gao J, Ding P, Gao Y. The role of endothelial cell\u2013pericyte interactions in vascularization and diseases. J Adv Res. 2025;67:269\u201388.","journal-title":"J Adv Res"},{"key":"1774_CR16","doi-asserted-by":"publisher","first-page":"15296","DOI":"10.1038\/ncomms15296","volume":"8","author":"D Park","year":"2017","unstructured":"Park D, Lee J, Kim J, et al. Plastic roles of pericytes in the blood\u2013retinal barrier. Nat Commun. 2017;8:15296.","journal-title":"Nat Commun"},{"key":"1774_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1083\/jcb.153.3.543","volume":"153","author":"M Hellstr\u00f6m","year":"2001","unstructured":"Hellstr\u00f6m M, Gerhardt H, Kal\u00e9n M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543\u201353.","journal-title":"J Cell Biol"},{"key":"1774_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.61.4.39","volume":"61","author":"D An","year":"2020","unstructured":"An D, Chandrasekera E, Yu D, et al. Non-proliferative diabetic retinopathy is characterized by nonuniform alterations of peripapillary capillary networks. Invest Ophthalmol Vis Sci. 2020;61:39.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1774_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med. 1994;331:1480\u20137.","journal-title":"New Engl J Med"},{"key":"1774_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018333","volume":"98","author":"HB Hwang","year":"2019","unstructured":"Hwang HB, Jee D, Kwon JW. Characteristics of diabetic macular edema patients with serous retinal detachment. Medicine (Baltimore). 2019;98: e18333.","journal-title":"Medicine (Baltimore)"},{"key":"1774_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108617","volume":"208","author":"P Escandon","year":"2021","unstructured":"Escandon P, Vasini B, Whelchel AE, Nicholas SE, Matlock HG, Ma JX, et al. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes. Exp Eye Res. 2021;208: 108617.","journal-title":"Exp Eye Res"},{"key":"1774_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2891-13-17","volume":"13","author":"B Grygiel-G\u00f3rniak","year":"2014","unstructured":"Grygiel-G\u00f3rniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutr J. 2014;13:1\u201310.","journal-title":"Nutr J"},{"key":"1774_CR23","volume":"2010","author":"S Kersten","year":"2010","unstructured":"Kersten S, Rakhshandehroo M, Knoch B, M\u00fcller M. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010: 612089.","journal-title":"PPAR Res"},{"key":"1774_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","volume":"30","author":"F Lalloyer","year":"2010","unstructured":"Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30:894.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1774_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","volume":"15","author":"A Sahebkar","year":"2017","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Watts GF, Serban M-C, Banach M. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017;15:22.","journal-title":"BMC Med"},{"key":"1774_CR26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.clinthera.2021.08.005","volume":"43","author":"MS Park","year":"2021","unstructured":"Park MS, Youn JC, Kim EJ, Han KH, Lee SH, Kim SH, et al. Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy: a multicenter, randomized, double-blind, phase IV study. Clin Ther. 2021;43:1735\u201347.","journal-title":"Clin Ther"},{"key":"1774_CR27","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.2337\/db13-0800","volume":"62","author":"JE Noonan","year":"2013","unstructured":"Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62:3968\u201375.","journal-title":"Diabetes"},{"key":"1774_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.exer.2018.09.016","volume":"178","author":"Z Lu","year":"2019","unstructured":"Lu Z, Li Y, Ru JH, Lopes-Virella MF, Lyons TJ, Huang Y. Interaction of palmitate and LPS regulates cytokine expression and apoptosis through sphingolipids in human retinal microvascular endothelial cells. Exp Eye Res. 2019;178:61\u201371.","journal-title":"Exp Eye Res"},{"key":"1774_CR29","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/j.ajpath.2014.06.021","volume":"184","author":"L Ding","year":"2014","unstructured":"Ding L, Cheng R, Hu Y, et al. Peroxisome proliferator-activated receptor \u03b1 protects capillary pericytes in the retina. Am J Pathol. 2014;184:2709\u201320.","journal-title":"Am J Pathol"},{"key":"1774_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2337\/db11-0413","volume":"62","author":"Y Chen","year":"2013","unstructured":"Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPAR\u03b1 agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62:261\u201372.","journal-title":"Diabetes"},{"key":"1774_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.804782","volume":"16","author":"L Guo","year":"2022","unstructured":"Guo L, Choi S, Bikkannavar P, Cordeiro MF. Microglia: key players in retinal ageing and neurodegeneration. Front Cell Neurosci. 2022;16: 804782.","journal-title":"Front Cell Neurosci"},{"key":"1774_CR32","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.3390\/cells11233869","volume":"11","author":"T Yuan","year":"2022","unstructured":"Yuan T, Dong L, Pearsall EA, et al. The protective role of microglial PPAR\u03b1 in diabetic retinal neurodegeneration and neurovascular dysfunction. Cells. 2022;11:3869.","journal-title":"Cells"},{"key":"1774_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00125-022-05655-z","volume":"65","author":"AJ Jenkins","year":"2022","unstructured":"Jenkins AJ, Grant MB, Busik JV. Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Diabetologia. 2022;65:587\u2013603.","journal-title":"Diabetologia"},{"key":"1774_CR34","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1167\/iovs.07-1440","volume":"49","author":"M Wu","year":"2008","unstructured":"Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:2679\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1774_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1089\/jop.2020.0068","volume":"36","author":"D Fu","year":"2020","unstructured":"Fu D, Yu J, Connell AR, Hookham MB, McLeese RH, Lyons TJ. Effects of modified low-density lipoproteins and fenofibrate on an outer blood\u2013retina barrier model: implications for diabetic retinopathy. J Ocul Pharmacol Ther. 2020;36:754\u201364.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1774_CR36","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"1774_CR37","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687\u201397.","journal-title":"Lancet"},{"issue":"1","key":"1774_CR38","first-page":"2545","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(1):2545\u201359.","journal-title":"N Engl J Med"},{"key":"1774_CR39","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group; ACCORD Eye Study Group, Chew EY, et al. 2010. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 363(1):233\u2013244.","DOI":"10.1056\/NEJMoa1001288"},{"key":"1774_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaophthalmol.2022.0633","volume":"140","author":"E Meer","year":"2022","unstructured":"Meer E, Bavinger JC, Yu Y, VanderBeek BL. Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2022;140:529\u201332.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1774_CR41","volume":"6","author":"SY Kataoka","year":"2023","unstructured":"Kataoka SY, Lois N, Kawano S, Kataoka Y, Inoue K, Watanabe N. Fenofibrate for diabetic retinopathy. Cochrane Database Syst Rev. 2023;6(6): CD013318.","journal-title":"Cochrane Database Syst Rev"},{"key":"1774_CR42","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400179","author":"D Preiss","year":"2024","unstructured":"Preiss D, Logue J, Sammons E, et al. Effect of fenofibrate on progression of diabetic retinopathy. NEJM Evid. 2024. https:\/\/doi.org\/10.1056\/EVIDoa2400179.","journal-title":"NEJM Evid"},{"key":"1774_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ekir.2018.09.006","volume":"4","author":"R Frazier","year":"2019","unstructured":"Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, et al. Associations of fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes. Kidney Int Rep. 2019;4:94\u2013102.","journal-title":"Kidney Int Rep"},{"key":"1774_CR44","first-page":"41","volume":"20","author":"C Hottelart","year":"1999","unstructured":"Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A. Le f\u00e9nofibrate augmente la cr\u00e9atinin\u00e9mie mais n\u2019alt\u00e8re pas le d\u00e9bit de filtration glom\u00e9rulaire chez les patients pr\u00e9sentant une insuffisance r\u00e9nale mod\u00e9r\u00e9e [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. Nephrologie. 1999;20:41\u20134.","journal-title":"Nephrologie"},{"key":"1774_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1159\/000064083","volume":"92","author":"C Hottelart","year":"2002","unstructured":"Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536\u201341.","journal-title":"Nephron"},{"key":"1774_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdiacomp.2017.09.014","volume":"32","author":"MB Brennan","year":"2018","unstructured":"Brennan MB, Huang ES, Lobo JM, Kang H, Guihan M, Basu A, Sohn MW. Longitudinal trends and predictors of statin use among patients with diabetes. J Diabetes Complications. 2018;32:27\u201333.","journal-title":"J Diabetes Complications"},{"key":"1774_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020151","volume":"15","author":"Y Morofuji","year":"2022","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, Tsutsumi K. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel). 2022;15: 151.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1774_CR48","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","volume":"13","author":"JD Collazos-Alem\u00e1n","year":"2022","unstructured":"Collazos-Alem\u00e1n JD, Gnecco-Gonz\u00e1lez S, Jaramillo-Zarama B, Jim\u00e9nez-Mora MA, Mendivil CO. The role of angiopoietins in neovascular diabetes-related retinal diseases. Diabetes Ther. 2022;13:1811\u201321.","journal-title":"Diabetes Ther"},{"key":"1774_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tcm.2022.11.003","volume":"34","author":"O Tomkins-Netzer","year":"2024","unstructured":"Tomkins-Netzer O, Niederer R, Lightman S. The role of statins in diabetic retinopathy. Trends Cardiovasc Med. 2024;34:128\u201335.","journal-title":"Trends Cardiovasc Med"},{"key":"1774_CR50","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/aos.12363","volume":"92","author":"R Tuuminen","year":"2014","unstructured":"Tuuminen R, Sahanne S, Loukovaara S. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol. 2014;92:675\u201381.","journal-title":"Acta Ophthalmol"},{"key":"1774_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3928\/15428877-20100430-04","volume":"41","author":"TD Panagiotoglou","year":"2010","unstructured":"Panagiotoglou TD, Ganotakis ES, Kymionis GD, Moschandreas JA, Fanti GN, Charisis SK. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol. Ophthalmic Surg Lasers Imaging. 2010;41:316\u201322.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1774_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8227(01)00341-2","volume":"56","author":"K Sen","year":"2002","unstructured":"Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1\u201311.","journal-title":"Diabetes Res Clin Pract"},{"key":"1774_CR53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3126\/nepjoph.v4i1.5846","volume":"4","author":"S Narang","year":"2012","unstructured":"Narang S, Sood S, Kaur B, Singh R, Mallik A, Kaur J. Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile. Nepal J Ophthalmol. 2012;4:23\u20138.","journal-title":"Nepal J Ophthalmol"},{"key":"1774_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/pds.5426","volume":"31","author":"E Meer","year":"2022","unstructured":"Meer E, Bavinger JC, Yu Y, Hua P, McGeehan B, VanderBeek BL. Statin use and the risk of progression to vision-threatening diabetic retinopathy. Pharmacoepidemiol Drug Saf. 2022;31:652\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1774_CR55","doi-asserted-by":"publisher","first-page":"16885","DOI":"10.1038\/s41598-024-67800-5","volume":"14","author":"R Zhao","year":"2024","unstructured":"Zhao R, Wang W, Zhang W, Lu J, Liu Y, Guo J, Yang L, Zhang Z, He C, Gu X, Wang B. Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study. Sci Rep. 2024;14:16885.","journal-title":"Sci Rep"},{"key":"1774_CR56","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1177\/1120672120922444","volume":"31","author":"R Pranata","year":"2021","unstructured":"Pranata R, Vania R, Victor AA. Statin reduces the incidence of diabetic retinopathy and its need for intervention: a systematic review and meta-analysis. Eur J Ophthalmol. 2021;31:1216\u201324.","journal-title":"Eur J Ophthalmol"},{"key":"1774_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13098-019-0488-9","volume":"11","author":"V Mozetic","year":"2019","unstructured":"Mozetic V, Pacheco RL, Latorraca COC, Riera R. Statins and\/or fibrates for diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:92.","journal-title":"Diabetol Metab Syndr"},{"key":"1774_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/ijem.ijem_480_21","volume":"26","author":"BAM Mounirou","year":"2022","unstructured":"Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic retinopathy: An overview of treatments. Indian J Endocr Metab. 2022;26:111\u20138.","journal-title":"Indian J Endocr Metab"},{"issue":"8","key":"1774_CR59","first-page":"2249","volume":"64","author":"A Nassaralla","year":"2023","unstructured":"Nassaralla A, Amaro M, Muccioli C, Vallory R, Morais F, Nassaralla JJ. Assessment of treatment of non-proliferative diabetic retinopathy with ranibizumab and aflibercept plus fenofibrate. Invest Ophthalmol Vis Sci. 2023;64(8):2249.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1774_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089518","volume":"14","author":"H Nguyen","year":"2024","unstructured":"Nguyen H, Kha R, Gopinath B, Mitchell P, Liew G. Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): study protocol for a randomised control trial. BMJ Open. 2024;14: e089518.","journal-title":"BMJ Open"},{"key":"1774_CR61","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"key":"1774_CR62","doi-asserted-by":"publisher","first-page":"26003","DOI":"10.1074\/jbc.M111.223164","volume":"286","author":"H Kato","year":"2011","unstructured":"Kato H, Gruenwald A, Suh JH, Miner JH, Barisoni-Thomas L, Taketo MM, et al. Wnt\/\u03b2-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011;286:26003\u201315.","journal-title":"J Biol Chem"},{"key":"1774_CR63","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI39492","volume":"120","author":"B Hartleben","year":"2010","unstructured":"Hartleben B, G\u00f6del M, Meyer-Schwesinger C, Liu S, Ulrich T, K\u00f6bler S, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010;120:1084\u201396.","journal-title":"J Clin Invest"},{"key":"1774_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10157-012-0711-6","volume":"17","author":"T Wada","year":"2013","unstructured":"Wada T, Shimizu M, Yokoyama H, Iwata Y, Sakai Y, Kaneko S, et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin Exp Nephrol. 2013;17:3\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1774_CR65","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2337\/db08-0061","volume":"57","author":"Y Qian","year":"2008","unstructured":"Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC. From fibrosis to sclerosis. Diabetes. 2008;57:1439\u201345.","journal-title":"Diabetes"},{"key":"1774_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0344-0338(11)81021-6","volume":"186","author":"A Bohle","year":"1990","unstructured":"Bohle A, Mackensen-Haen S, von Gise H, Grund KE, Wehrmann M, Batz Ch, et al. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. Pathol Res Pract. 1990;186:135\u201344.","journal-title":"Pathol Res Pract"},{"key":"1774_CR67","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2147\/DDDT.S405266","volume":"17","author":"C Tang","year":"2023","unstructured":"Tang C, Deng X, Qu J, Miao Y, Tian L, Zhang M, et al. Fenofibrate attenuates renal tubular cell apoptosis by up-regulating MCAD in diabetic kidney disease. Drug Des Dev Ther. 2023;17:1503\u201314.","journal-title":"Drug Des Dev Ther"},{"key":"1774_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12944-020-01254-2","volume":"19","author":"X Sun","year":"2020","unstructured":"Sun X, Liu J, Wang G. Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids Health Dis. 2020;19:103.","journal-title":"Lipids Health Dis"},{"key":"1774_CR69","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TME Davis","year":"2011","unstructured":"Davis TME, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:280\u201390.","journal-title":"Diabetologia"},{"key":"1774_CR70","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.neuron.2023.05.003","volume":"111","author":"SA Eid","year":"2023","unstructured":"Eid SA, Rumora AE, Beirowski B, Bennett DL, Hur J, Savelieff MG, Feldman EL. New perspectives in diabetic neuropathy. Neuron. 2023;111:2623\u201341.","journal-title":"Neuron"},{"key":"1774_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083204","volume":"9","author":"YR Cho","year":"2014","unstructured":"Cho YR, Lim JH, Kim MY, Kim TW, Hong BY, Kim YS, Chang YS, Kim HW, Park CW. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db\/db mice. PLoS ONE. 2014;9: e83204.","journal-title":"PLoS ONE"},{"key":"1774_CR72","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00125-007-0919-2","volume":"51","author":"TM Davis","year":"2008","unstructured":"Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51:562\u20136.","journal-title":"Diabetologia"},{"key":"1774_CR73","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2337\/db22-0611","volume":"72","author":"CHY Teo","year":"2023","unstructured":"Teo CHY, Lin MT, Lee IXY, Koh SK, Zhou L, Goh DS, Choi H, Koh HWL, Lam AYR, Lim PS, Mehta JS, Kovalik JP, Coffman TM, Tan HC, Liu YC. Oral peroxisome proliferator-activated receptor-\u03b1 agonist enhances corneal nerve regeneration in patients with type 2 diabetes. Diabetes. 2023;72:932\u201346.","journal-title":"Diabetes"},{"key":"1774_CR74","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","volume":"373","author":"K Rajamani","year":"2009","unstructured":"Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D\u2019Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373:1780\u20138.","journal-title":"Lancet"},{"key":"1774_CR75","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00125-012-2524-2","volume":"55","author":"DE Bonds","year":"2012","unstructured":"Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55:1641\u201350.","journal-title":"Diabetologia"},{"key":"1774_CR76","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","volume":"95","author":"PH Jones","year":"2005","unstructured":"Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120\u20132.","journal-title":"Am J Cardiol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01774-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:13:13Z","timestamp":1756897993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01774-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1774"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01774-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Parra-Pineda A, Lizarazo-Bocanegra S, Villalba-Montero LF, Ayala-Quintero CC, Losada-D\u00edaz F, Correa-Osio I, Lizarazo-Rojas LA and Mendivil CO have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}